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Accepted 1 July; published on WWW 13 August 1998Dystrophin-related and associated proteins are important
for the formation and maintenance of the mammalian
neuromuscular junction. Initial studies in the electric organ
of Torpedo californica showed that the dystrophin-related
protein dystrobrevin (87K) co-purifies with the
acetylcholine receptors and other postsynaptic proteins.
Dystrobrevin is also a major phosphotyrosine-containing
protein in the postsynaptic membrane. Since inhibitors of
tyrosine protein phosphorylation block acetylcholine
receptor clustering in cultured muscle cells, we examined
the role of a -dystrobrevin during synapse formation and in
response to agrin. Using specific antibodies, we show that
C2 myoblasts and early myotubes only produce a -
dystrobrevin-1, the mammalian orthologue of Torpedo
dystrobrevin, whereas mature skeletal muscle expresses
three distinct a -dystrobrevin isoforms. In myotubes, a -
dystrobrevin-1 is found on the cell surface and also in
acetylcholine receptor-rich domains. Following agrin
stimulation, a -dystrobrevin-1 becomes re-localised beneath
the cell surface into macroclusters that contain
acetylcholine receptors and another dystrophin-related
protein, utrophin. This redistribution is not associated with
tyrosine phosphorylation of a -dystrobrevin-1 by agrin.
Furthermore, we show that a -dystrobrevin-1 is associated
with both utrophin in C2 cells and dystrophin in mature
skeletal muscle. Thus a -dystrobrevin-1 is a component of
two protein complexes in muscle, one with utrophin at the
neuromuscular junction and the other with dystrophin at
the sarcolemma. These results indicate that a -
dystrobrevin-1 is not involved in the phosphorylation-
dependent, early stages of receptor clustering, but rather
in the stabilisation and maturation of clusters, possibly via
an interaction with utrophin.
Key words: Dystrobrevin, Utrophin, Agrin, Acetylcholine receptor
(AChR) clustering, Muscle
SUMMARYINTRODUCTION
A key event in the formation of synapses is the accumulation
of neurotransmitter receptor proteins at the postsynaptic
membrane, directly opposite the presynaptic nerve terminal.
During the development of the neuromuscular junction (NMJ),
the nicotinic acetylcholine receptor (AChR) undergoes a
dramatic relocalisation and aggregates at high density in the
plasma membrane juxtaposed to the nerve terminal (Hall and
Sanes, 1993). The innervating motor nerve regulates this
accumulation through synapse-specific induction of gene
expression and via post-translational mechanisms (Duclert and
Changeux, 1995). The extracellular matrix (ECM) protein
agrin is involved in the post-translation clustering of AChRs
and also plays a role in the induction of synapse-specific gene
expression (reviewed by Ruegg and Bixby, 1998).
Members of the dystrophin-associated protein complex
(DPC) and dystrophin-related proteins have been implicated in
synaptic structure and function. The dystrophin-deficient mdx
mouse has an increase in the rate of AChR degradation similar
to that observed following denervation (Xu and Salpeter,
1997). These mice also have morphologically abnormal NMJs,characterised by a reduction in the number of junctional folds
(Lyons and Slater, 1991). The dystrophin-associated protein,
a -dystroglycan, is the major agrin-binding protein in muscle
and other tissues; however, a -dystroglycan is unlikely to be a
functional agrin-receptor (Meier et al., 1996; Gesemann et al.,
1998). Although the absence of dystrophin results in loss of
the DPC from the extra-synaptic sarcolemma, dystrophin-
associated proteins are still retained at the NMJ through an
association with the dystrophin-related protein, utrophin
(Matsumara et al., 1992). In normal adult muscle utrophin is
found exclusively at the NMJ (Ohlendieck et al., 1991). Similar
to the mdx mouse, utrophin-deficient mice have a reduction in
the number of junctional folds at a single synapse (Deconinck
et al., 1997; Grady et al., 1997). Thus, the specialised
postsynaptic cytoskeleton of the NMJ appears to contain a
modified DPC that is required to maintain normal synaptic
structure.
To determine the function of other dystrophin-related
proteins at the synapse, we have focused our studies on a -
dystrobrevin (also known as 87K protein or A0). Dystrobrevin
was originally identified in the Torpedo electric organ as a
component of the postsynaptic membrane that co-purified with
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1989; Butler et al., 1992; Wagner et al., 1993; Kramarcy et al.,
1994; Dwyer and Froehner, 1995). Although a -dystrobrevin is
closely associated with the AChRs, monoclonal antibodies
raised against this protein label the sarcolemma as well as the
NMJ of rodent skeletal muscle (Carr et al., 1989). Interestingly,
dystrobrevin is a dystrophin-related protein that is
phosphorylated on tyrosine and serine residues, suggesting that
its function may be regulated by post-translation modification
(Wagner et al., 1993; Wagner and Huganir, 1994).
By contrast to the initial description of dystrobrevin in
Torpedo, we have shown that several a -dystrobrevin isoforms
are expressed in different mouse tissues (Blake et al., 1996;
Ambrose et al., 1997). In skeletal muscle these are: a -
dystrobrevin-1 (94 kDa), a -dystrobrevin-2 (62 kDa) and a -
dystrobrevin-3 (42 kDa), described herein. a -dystrobrevin-1 is
the orthologue of the Torpedo 87K protein and contains a ZZ
domain (Ponting et al., 1996), two predicted a -helical coiled-
coil motifs (Blake et al., 1995) and a C-terminal tyrosine kinase
substrate domain (Wagner et al., 1993; Blake et al., 1996).
Alternative splicing in cardiac and skeletal muscle generates
a -dystrobrevin-1 and -2 transcripts that differ from their brain
counterparts by the inclusion of the vr3 sequence preceding the
coiled-coil encoding region (Blake et al., 1996; Ambrose et al.,
1997). It has been established that a -dystrobrevin binds to
syntrophin and dystrophin in different tissues (Kramarcy et al.,
1994; Blake et al., 1996; Peters et al., 1997a). However, the
antibodies used in these studies do not distinguish between a -
dystrobrevin-1 and -2, and the recently identified paralogue, b -
dystrobrevin (Peters et al., 1997b; Blake et al., 1998). Thus,
the exact protein interactions involving dystrobrevin isoforms
have not yet been elucidated.
Since a -dystrobrevin is known to be associated with AChRs
and is also thought to be part of the DPC, we have studied the
role of the different a -dystrobrevin isoforms during synapse
formation and in normal muscle. We have identified three
different a -dystrobrevin isoforms that are expressed in mature
skeletal muscle. Using a -dystrobrevin-1 specific antisera, we
show that a -dystrobrevin-1 is localised at the sarcolemma and
NMJ of normal muscle but is restricted to the NMJ in
dystrophin-deficient mdx muscle. In cultured myotubes, a -
dystrobrevin-1 is distributed on the cell surface but is enriched
in AChR-containing clusters. Following agrin stimulation, a -
dystrobrevin-1 is dramatically re-localised into AChR-
containing macroclusters. However, agrin stimulation does not
induce tyrosine phosphorylation of a -dystrobrevin-1, in
contrast to nicotinic AChRs (Wallace et al., 1995). a -
dystrobrevin-1 co-immunoprecipitates with utrophin in
myotubes and with dystrophin in adult skeletal muscle. We
conclude that a -dystrobrevin-1 is a component of two protein
complexes, one with dystrophin at the sarcolemma and one
with utrophin at the NMJ. a -dystrobrevin-1, in association with
utrophin, may be involved in the maturation of the postsynaptic
cytoskeleton at the developing NMJ.
MATERIALS AND METHODS
Molecular biology
The human dystrobrevin-3 cDNA clones were isolated from a human
foetal brain cDNA library prepared in the plasmid vector pcDNA2(Invitrogen) as described previously (Blake et al., 1996). The murine
dystrobrevin-3 cDNAs were isolated from muscle first-strand cDNA
by reverse-transcriptase PCR using the following primers: PSP3F 5 ¢ -
CTGTAACCAGCATGAACGAC and PSP3.1R 5¢ -CAGCTTTAT-
TGAACAGCACCC, with Pfu polymerase (Stratagene), following the
manufacturer’s instructions. PCR products were incubated with Taq
polymerase (Perkin Elmer) for 30 minutes at 72°C, purified and
subcloned in to pGEM-T (Promega). Multiple clones were sequenced
with Sequenase version 2.0 (Amersham) to check for mutations that
may have occurred during PCR. Human multiple tissue northern blots
were purchased from Clontech and hybridised following the
manufacturer’s instructions.
Antibodies
The following primary antibodies used in our experiments have been
described previously or are available commercially: horseradish
peroxidase (HRP)-conjugated anti-phosphotyrosine mAb 4G10
(Upstate Biotechnology), polyclonal anti-dystrophin P6 antiserum
(Sherratt et al., 1992), anti-utrophin monoclonal antibody (mAb)
MANCHO3 (Nguyen et al., 1991), anti- b -dystroglycan mAb
43DAG1/8D5 (NovoCastra), anti-vimentin/desmin mAb IFA (Pruss et
al., 1981), polyclonal anti-MuSK Nsk2Fc antiserum (Meier et al.,
1997). In addition, we used an anti-a -dystrobrevin-1 ( a 1CT-FP)
polyclonal antiserum that was generated against a fusion protein
containing 107 amino acids of the unique carboxy terminus of a -
dystrobrevin-1 and an anti- b -dystrobrevin (b CT-FP) polyclonal
antiserum that was generated against a fusion protein containing the
last 306 amino acids of b -dystrobrevin (Blake et al., 1998). In muscle
the b CT-FP polyclonal only detects a -dystrobrevin-1 and -2 (Blake et
al., 1998).
Agrin and peroxivanadate
The generation of recombinant agrin is described elsewhere
(Gesemann et al., 1995). Agrin treatment of day-6 myotubes was
performed by washing cells once in pre-warmed differentiation
medium, and incubating them at 37°C in differentiation medium
supplemented with C95A4B8 agrin. Incubation times were 16 hours in
clustering experiments and shorter periods for the analysis of tyrosine
phosphorylation (see Fig. 7). 1 nM C95A4B8 agrin was used for
clustering experiments and 10 nM C95A4B8 agrin for phosphotyrosine
experiments. Control experiments were performed in parallel using 1
nM C95A0B0, the clustering-deficient agrin isoform, or no agrin.
Sodium peroxivanadate was prepared by mixing 100 m l of 100 mM
sodium pervanadate and 200 m l of 100 mM H2O2 and diluting it into
9.7 ml serum-free medium immediately before use. Cultures were
washed once with serum-free DME medium and treated with
peroxivanadate for 15 minutes.
Cell culture
C2C12 mouse muscle cells (Yaffe and Saxel, 1977) were routinely
cultured in 175 cm2 tissue culture flasks in DMEM supplemented with
10% foetal calf serum (Globefarm Ltd.), glutamine and antibiotics.
For immunofluorescence studies, cells were transferred onto gelatine-
coated coverslips and stained as described below. For biochemical
experiments, cells were cultured in the original 35 mm dish and
processed as described below. Myoblast fusion was induced by
culturing the cells in DMEM supplemented with 5% horse serum,
glutamine and antibiotics (differentiation medium). Early myotubes
appeared within 3 days, late myotubes after 6 days.
Immunofluorescence microscopy
8 m m cryosections, prepared from adult skeletal muscle of normal C57
and mdx mutant mice as described previously (Deconinck et al.,
1997), were stained as described below. Cells growing on coverslips
were rinsed in phosphate-buffered saline (PBS), and fixed for 20
minutes at room temperature in PBS containing 1%
paraformaldehyde, 100 mM L-lysine, 10 mM sodium metaperiodate
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10 minutes in PBS containing 1% Triton X-100, washed three times
in PBS and stored overnight at 4°C in PBS. All subsequent steps were
carried out at room temperature. Coverslips were incubated for 1 hour
in blocking buffer (PBS containing 5% fraction V bovine serum
albumin, 5% fetal calf serum and 0.1% sodium azide) followed by 1
hour incubation with the primary antibody. The antibody dilutions
were 1:500 for the a 1CT-FP and b CT-FP polyclonal antisera, and
1:100 for the P6 polyclonal antiserum and for mAbs MANCHO3 and
43DAG1/8D5. Coverslips were washed three times for 10 minutes in
PBS, and incubated for 1 hour with affinity-purified FITC-conjugated
donkey anti-mouse or anti-rabbit IgG (diluted 1:100; Jackson
ImmunoResearch Laboratories, Inc.). After three washes in PBS,
coverslips were incubated for 1 hour with rhodamine-conjugated a -
bungarotoxin (diluted 1:3000; Molecular Probes, Inc.), followed by
three washes in PBS and mounting in Vectashield mounting medium
(Vector Laboratories). Labelled cells were analysed and photographed
on a Leica DM RBE Microscope using N FLUOTAR 40· lenses.
Negative control experiments were performed with rabbit pre-immune
serum (diluted 1:500) or without primary antibodies alone.
Immunoprecipitation
Immunoprecipitation experiments were carried out on C2 cell
lysates prepared from 100 mm tissue culture dishes. Cells were
rinsed with ice-cold PBS and incubated for 15 minutes on ice in 1 ·
RIPA buffer (500 mM NaCl, 50 mM Tris, pH 7.4, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate,
1 m g/ml leupeptin, 1 m g/ml aprotinin and 10 m g/ml pepstatin) or lysis
buffer for phosphotyrosine experiments (150 mM NaCl, 50 mM
Tris, pH 7.5, 5 mM EDTA, 5 mM EGTA, 50 mM NaF, 10 mM
sodium molybdate, 1% Triton X-100, 1 mM sodium orthovanadate,
1 m g/ml leupeptin, 1 m g/ml aprotinin and 10 m g/ml pepstatin). The
subsequent steps were carried out at 4°C. Cell lysates were
collected, sonicated three times for 10 seconds, and centrifuged at
20,000 g for 15 minutes to remove insoluble material. For
immunoprecipitation, 0.5-1 mg of soluble protein was incubated
overnight with 2 m l a 1CT-FP antiserum or 2 m l anti-MuSK
antiserum, followed by recovery with protein A-Sepharose
(Pharmacia) for 1 hour at 4°C. Sepharose-pellets were washed three
times in 1 · RIPA buffer containing 1% Triton X-100, and once in
PBS. Proteins were eluted from protein A-Sepharose with urea/SDS
buffer (75 mM Tris, pH 6.8, 3.8% SDS, 4 M urea, 5% b -
mercaptoethanol, 20% glycerol) and analysed by western blotting.
Control experiments were performed with 2 m l pre-immune serum
or without antiserum. a -dystrobrevin-1 and dystrophin were co-
immunoprecipitated from 500 m g of RIPA-solubilised mouse muscle
protein as described above.
Immunoblot analysis
Proteins were separated by electrophoresis on 8% SDS-
polyacrylamide gels and electrophoretically transferred onto
nitrocellulose membranes (Schleicher und Schuell). The following
steps were carried out at room temperature. Membranes were
incubated for 1 hour in blocking buffer (Tris-buffered saline
containing 0.1% Tween-20 and 5% non-fat dry milk, or 3% fraction
V bovine serum albumin instead of dry milk for phosphotyrosine
experiments), and incubated for 1 hour with the following primary
antibodies; mAb 4G10 (1:5000), P6 polyclonal antiserum (1:1000),
a 1CT-FP polyclonal antiserum (1:500), b CT-FP polyclonal
antiserum (1:1000), mAbs MANCHO3 and IFA (1:100), mAb
43DAG1/8D5 (1:20). Membranes were washed three times for 10
minutes in blocking buffer and incubated for 1 hour with HRP-
conjugated donkey anti-mouse or anti-rabbit IgG (diluted 1:3500;
Jackson ImmunoResearch Laboratories, Inc.). Western blots were
developed with the BM chemiluminescence substrate system
according to the manufacturer’s instructions (Boehringer-
Mannheim).RESULTS
Dystrobrevin isoforms in muscle
Previously we have described the two dystrobrevin isoforms,
a -dystrobrevin-1 and -2 in mouse brain (Blake et al., 1996).
Hybridisation of a probe derived from the 5¢ end of the
dystrobrevin cDNA to multiple tissue northern blots shows a
complex pattern of transcripts in different tissues (Fig. 1A,
upper panel). In skeletal and cardiac muscle the most intensely
hybridising transcript is 1.7 kb. This transcript does not
correspond to the a -dystrobrevin-1 and -2 mRNAs (Blake et
al., 1996; Ambrose et al., 1997). To complete our description
of a -dystrobrevin isoforms in muscle we cloned the human and
mouse cDNAs corresponding to the 1.7 kb muscle-expressed
transcript. The protein product of this transcript has been
named a -dystrobrevin-3. A northern blot was hybridised with
a probe covering the unique 3 ¢ untranslated region of a -
dystrobrevin-3 and shows that a -dystrobrevin-3 is only
expressed in skeletal and cardiac muscle.
Conceptual translation of the a -dystrobrevin-3 cDNA
predicts a protein with a relative molecular mass of 42 kDa
(Fig. 1B). a -dystrobrevin-3 has a unique 9-amino-acid C-
terminal sequence and a short 3 ¢ untranslated region. The
predicted a -dystrobrevin-3 protein contains two structural
motifs that are characteristic of the dystrophin-family of related
proteins, namely the EF-hands and ZZ domain (Ponting et al.,
1996; Roberts and Bobrow, 1998). These structural features are
conserved amongst the dystrophin-related proteins in
vertebrates and invertebrates and can therefore be predicted to
be functionally important (Roberts and Bobrow, 1998). The
primary sequences of human and mouse a -dystrobrevin-3 are
highly homologous, differing at only four residues. However
only one of these residues is in the unique C-terminal encoding
region of a -dystrobrevin-3. The remainder of the sequence of
a -dystrobrevin-3 is identical to the common regions of a -
dystrobrevin-1 and -2. No murine expressed sequence tags
(EST) were identified that were identical or homologous to the
unique region of a -dystrobrevin-3, which is encoded by exon
11 (Ambrose et al., 1997). The human a -dystrobrevin-3
specific sequence described herein, and previously by
Sadoulet-Puccio et al. (1996), also has no EST homologue,
despite its abundance in muscle and proximity to the 3 ¢ end of
the mRNA.
The sequences of the 3¢ untranslated regions of human and
mouse a -dystrobrevin-3 are homologous (Fig. 1C).
Interestingly, our results obtained by northern blotting show
that a -dystrobrevin-3 is encoded by a single transcript whereas
a -dystrobrevin-1 and -2 are encoded by a least two different
transcripts (Blake et al., 1996; Ambrose et al., 1997). The
organisation of each of the a -dystrobrevin isoforms expressed
in muscle is shown in Fig. 1D.
a -dystrobrevin-1 is a dystrophin-associated protein
in skeletal muscle
Since a -dystrobrevin-1 is the mammalian orthologue of the
Torpedo 87K protein (Wagner et al., 1993) we used a specific
antibody, a 1CT-FP (Blake et al., 1998), to determine the
location of a -dystrobrevin-1 in muscle. This study differs
from previously described experiments that did not use
isoform-specific antisera. Frozen sections of normal mouse
2598 R. Nawrotzki and others
B
         AGCGGACCCGGCACTTCCAACATTATTAAATAATAAGAAAGCGGCTCCACTCAGGCACAA
         ACCTCCCTGCAGACCAATGGACGCCTTCTAAGAGTTTGGCGAGTCAGTGACTGAAGCGCC
         CGTCCATTCCAAGATAAATAGGATTTACCAATCCTTGGATGAAGTGCTTGGGAAGTCTTT
         AAGTGCCATAATCAACTGCCATTTCAAAGAATATAGATGGTTTTGAAAAGTTCATGCTGT
         CCCTTCATTGAATTTTAGAATGATTGAAGATAGTGGGAAAAGAGGAAATACCATGGCAGA
Human                        M  I  E  D  S  G  K  R  G  N  T  M  A  E
Mouse                        .  .  .  .  .  .  .  .  .  .  .  .  .  .
         AAGAAGACAGCTGTTTGCAGAGATGAGGGCTCAAGATCTGGATCGCATCCGACTCTCCAC
           R  R  Q  L  F  A  E  M  R  A  Q  D  L  D  R  I  R  L  S  T
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         CTACAGAACAGCATGCAAGCTTAGGTTTGTTCAGAAGAAATGCAATTTGCACCTGGTGGA
           Y  R  T  A  C  K  L  R  F  V  Q  K  K  C  N  L  H  L  V  D
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         CATATGGAATGTCATAGAAGCATTGCGGAAAAATGCTCTGAACAACCTGGACCCAAACAC
           I  W  N  V  I  E  A  L  R  K  N  A  L  N  N  L  D  P  N  T
           .  .  .  .  .  .  .  .  .  E  .  .  .  .  .  .  .  .  .  I
         TGAACTCAACGTGTCCCGCTTGGAGGCTGTGCTCTCCACTATTTTTTACCAGCTCAACAA
           E  L  N  V  S  R  L  E  A  V  L  S  T  I  F  Y  Q  L  N  K
           .  .  .  .  A  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         ACGGATGCCAACCACTCACCAAATCCATGTGGAGCAGTCCATCAGCCTCCTCCTTAACTT
           R  M  P  T  T  H  Q  I  H  V  E  Q  S  I  S  L  L  L  N  F
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         CCTGCTTGCAGCGTTTGATCCGGAAGGCCATGGTAAAATTTCAGTATTTGCTGTCAAAAT
           L  L  A  A  F  D  P  E  G  H  G  K  I  S  V  F  A  V  K  M
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         GGCTTTAGCCACATTGTGTGGAGGGAAGATCATGGACAAATTAAGATATATTTTCTCAAT
           A  L  A  T  L  C  G  G  K  I  M  D  K  L  R  Y  I  F  S  M
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         GATTTCTGACTCCAGTGGGGTGATGGTTTATGGACGATATGACCAATTCCTTCGGGAAGT
           I  S  D  S  S  G  V  M  V  Y  G  R  Y  D  Q  F  L  R  E  V
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         TCTCAAACTACCCACGGCAGTTTTTGAAGGTCCTTCATTTGGTTACACAGAACAGTCAGC
           L  K  L  P  T  A  V  F  E  G  P  S  F  G  Y  T  E  Q  S  A
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         CAGATCCTGTTTCTCCCAACAGAAAAAAGTCACGTTAAATGGTTTCTTGGACACGCTTAT
           R  S  C  F  S  Q  Q  K  K  V  T  L  N  G  F  L  D  T  L  M
    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         GTCAGATCCTCCCCCGCAGTGTCTGGTCTGGTTGCCTCTTCTGCATCGACTAGCAAATGT
    S  D  P  P  P  Q  C  L  V  W  L  P  L  L  H  R  L  A  N  V
    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         GGAAAATGTCTTCCATCCGGTTGAGTGTTCCTACTGCCACAGTGAGAGTATGATGGGATT
    E  N  V  F  H  P  V  E  C  S  Y  C  H  S  E  S  M  M  G  F
    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         TCGCTACCGATGCCAACAGTGTCACAATTACCAGCTCTGTCAGGACTGCTTCTGGAGGGG
           R  Y  R  C  Q  Q  C  H  N  Y  Q  L  C  Q  D  C  F  W  R  G
    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         ACATGCCGGTGGTTCTCATAGCAACCAGCACCAAATGAAAGAGTACACGTCATGGAAATC
    H  A  G  G  S  H  S  N  Q  H  Q  M  K  E  Y  T  S  W  K  S
    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         ACCTGCTAAGAAGCTGACTAATGCATTAAGCAAGTCCCTGAGCTGTGCTTCCAGCCGTGA
    P  A  K  K  L  T  N  A  L  S  K  S  L  S  C  A  S  S  R  E
    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         ACCTTTGCACCCCATGTTCCCAGATCAGCCTGAGAAGCCACTCAACTTGGCTCACATCGT
           P  L  H  P  M  F  P  D  Q  P  E  K  P  L  N  L  A  H  I  V
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         TGATACTTGGCCTCCCAGACCTGTAACCAGCATGAACGACACCCTGTTCTCCCACTCTGT
           D  T  W  P  P  R  P  V  T  S  M  N  D  T  L  F  S  H  S  V
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
         TCCCTCCTCAGGAAGTCCTTTTATTACCAGGAGCTCGGACGGTGCTTTTGGTGGATGCGT
    P  S  S  G  S  P  F  I  T  R  S  S  D  G  A  F  G  G  C  V
           .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  H  .  .  .  .
         CTAGATGGATAACATGACTTCTTCTACCCTAAAATATTCCTATAATACTTTGAGCTGTTC
           *
           .
         TGGTTCCTCCAGGGTGCATGGTACCCATTAACCCAAAATATGATTATTTCCCTTTTTTCC
         CATTTTCAGTCATTTTGGAATGTTCTCTGTGAACCACAGTTGTGTTGTTTAAAGCTCACA
         TTTCTTTCTGTCACCACAGAGATTGGCCTACGGTTTCTGTTTTGAGGGTGCTGTTCAATA
         AAGCTGTGTACACTAAAAAAAAAA
C
 Human TCGGACGGTGCTTTTGGTGGATGCGTCTAGATGGATAACATGACTTCTTC
 |||||||| ||   ||||||||||||||||||||||||||||||||| | 
 Mouse TCGGACGGCGCCCATGGTGGATGCGTCTAGATGGATAACATGACTTCCTG
TACCCTAAAATATTCCTATAATACTTTGAGCTGTTCTGGTTCCTCCAGGG
| |||||||||||| ||| ||  | ||||||| ||||| |||||      
TTCCCTAAAATATTTCTA.AACCCCTTGAGCT.TTCTGCTTCCT......
TGCATGGTACCCATTAACCCAAAATATGATTATTTCCCTTTTTTCCC.AT
   | ||||||| | | |    ||  |||||||| ||||| ||
..........CTATTAACCAAGAGTTGAGTTGCTTCCCTTTCTTCCCAAT
     
TTTCAGTCATTTTGGAATGTTCTCTGTGAACCACAGTTGTGTTGTTTAAA
|||||||| | |||   ||||| ||||||||||||| |   || | ||||
TTTCAGTCCTCTTGTCTTGTTCCCTGTGAACCACAGAT...TTCTATAAA
     
GCTCACATTTCTTTCTGTCACCACAGAGATTGGCCTACGGTTTCTGTTTT




















Dmuscle were stained with a 1CT-FP, which is raised against the
unique carboxy terminus of a -dystrobrevin-1 (Blake et al.,
1998). a -dystrobrevin-1 was localised at the entire
circumference of the sarcolemma and enriched at the NMJ
(Fig. 2). However, when muscle sections from the dystrophin-deficient mdx muscle were analysed, the a -dystrobrevin-1
staining was lost from the sarcolemma, but was still
concentrated at the NMJ (Fig. 2). These data suggest that a -
dystrobrevin-1 is a dystrophin-associated protein at the
sarcolemma but may also bind to utrophin at the NMJ. These
data were also confirmed and extended with a second
antibody, b CT-FP, that detects a -dystrobrevin -1 and -2 and
b -dystrobrevin (Blake et al., 1998). This antibody strongly
labels the sarcolemma and NMJ of normal muscle (Fig. 2E).
In common with the antibody that only detects a -
dystrobrevin-1, the labelling at the sarcolemma with b CT-FP
is severely reduced but retained at the NMJ (Fig. 2G). This
labelling pattern is not attributable to cross-reaction with b -
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Fig. 1. a -dystrobrevin isoforms expressed in muscle. (A) Northern
blot analysis of a -dystrobrevin in muscle. (Upper panel) Human
multiple tissue northern blot hybridised with a probe derived from
the 5¢ end of the human a -dystrobrevin cDNA that detects all a -
dystrobrevin isoforms. The major hybridising transcripts are
indicated. An asterisk denotes that a -dystrobrevin-1 and -2 are
encoded by two different transcripts (Ambrose et al., 1997), only the
larger of which is shown. (Lower panel) The same northern blot
hybridised with a probe derived from the 3¢ untranslated region of a -
dystrobrevin-3. Lane 1, heart; lane 2, brain; lane 3, placenta; lane 4,
lung; lane 5, liver; lane 6, skeletal muscle; lane 7, kidney; lane 8,
pancreas. The sizes of the molecular mass markers in kb are
indicated. (B) The sequence of human and mouse a -dystrobrevin-3.
The nucleotide and primary sequence of human a -dystrobrevin-3 is
shown. The mouse primary sequence is shown beneath the human
sequence. Only amino acid differences are shown. (C) The sequence
of the human and mouse a -dystrobrevin-3 3¢ regions. The sequences
of the 3 ¢ unique regions of human and mouse a -dystrobrevin-3 are
compared. The stop codons are shown in bold typeface. The putative
polyadenylation consensus sequences are underlined. (D) a -
dystrobrevin isoforms expressed in muscle. Diagram showing the
domain organisation of the three a -dystrobrevin isoforms expressed
in mature mammalian skeletal muscle, together with b -dystrobrevin.
The vr3 sequence is only expressed in muscle but is not found in a -
dystrobrevin-3 (Blake et al., 1996). EF, EF-hand region; ZZ, ZZ
domain (Ponting et al., 1996); vr3, variable region 3; CC, coiled-coil
domain (Blake et al., 1995); Y, tyrosine kinase substrate domain.dystrobrevin because b -dystrobrevin is not expressed in
myofibres but is present in peripheral nerves often found in
muscle sections (D. J. B., unpublished observation). It can
therefore be concluded that levels of a -dystrobrevins-1 and -
2 are reduced at the sarcolemma of the mdx mouse, indicating
that both proteins are likely to be dystrophin-associated. These
data agree with studies of a -dystrobrevin localisation in the
muscles of DMD patients that were performed using
antibodies that were not isoform-specific (Metzinger et al.,
1997).
To demonstrate an association between a -dystrobrevin-1
and dystrophin in skeletal muscle, reciprocal
immunoprecipitation experiments were performed with a -
dystrobrevin-1- and dystrophin-specific antisera. Dystrophin is
co-immunoprecipitated with the a 1CT-FP antisera but not with
an unrelated antibody or the pre-immune sera (Fig. 3A). This
association was confirmed by co-immunoprecipitating a -
dystrobrevin-1 with the anti-dystrophin P6 polyclonal antisera
(Fig. 3B). These results show that a -dystrobrevin-1 is a
dystrophin-associated protein but may also bind to utrophin,
since a -dystrobrevin-1 is retained at the NMJ in mdx mouse
muscle.
Co-expression of a -dystrobrevin-1 and utrophin in
cultured C2 myotubes
To investigate whether a -dystrobrevin is involved in synapse
formation, we examined the role of a -dystrobrevin in C2
myotubes, a system frequently used by researchers studying
the events of synaptogenesis in vitro. Northern and western
blots showed that the a -dystrobrevin-1 is the major
dystrobrevin isoform expressed in C2 cells (data not shown).
The expression pattern of a -dystrobrevin-1 was determined
by western blot analysis of protein extracts prepared from
C2 cells at different time points during myoblast fusion. Thea 1CT-FP antiserum detects two proteins of similar relative
mobility (Fig. 4, a -db-1). In proliferating myoblasts (d0), a -
dystrobrevin-1 is found at low levels, consistent with our
detection of a -dystrobrevin-1 mRNA in undifferentiated C2
myoblasts (data not shown). Within 1 day after switching to
differentiation medium, a -dystrobrevin-1 becomes more
abundant and remains expressed at similar levels as myoblast
fusion proceeds. After 2 days in differentiation medium, a
second protein with relative higher molecular mass is
detected with the a 1CT-FP antibody. This high molecular
mass isoform is probably an alternatively spliced form of a -
dystrobrevin-1 containing the muscle expressed vr3
sequence (Blake et al., 1996). The b CT-FP antibody was
used to determine the expression pattern of a -dystrobrevin-
2 in C2 cells. This antibody detects a -dystrobrevin-1 and -2
in C2 cells; however, due to their different molecular mass,
these proteins can be easily resolved on SDS-PAGE gels
(Blake et al., 1998). a -dystrobrevin-2 is detected in late
myotubes and appears to parallel the expression of
dystrophin (Fig. 4, a -db-2).
Utrophin and dystrophin are potential binding partners for
a -dystrobrevin-1 in C2 myotubes. To determine their
expression pattern in C2 cells, identical western blots were
developed with the utrophin- and dystrophin-specific
antibodies. Utrophin is present at similar levels in proliferating
myoblasts and differentiating myotubes (Fig. 4, utro). By
contrast, dystrophin is not detected in myoblasts and early
myotubes, but is detectable at later stages of myotube
formation (Fig. 4, dys). b -dystroglycan, vimentin and desmin
were analysed as internal controls for the co-ordinate gene
expression during myoblast fusion (Fig. 4, b -dg, vim, des).
These data show that members of the dystrophin protein
family and their associated proteins are differentially
expressed in C2 myotubes, and only utrophin and dystrobrevin
are co-expressed during myoblast fusion and in early
myotubes.
Co-localisation of a -dystrobrevin-1, utrophin and
AChR in cultured C2 myotubes
Double-labelling experiments, using the anti- a -dystrobrevin-1
antiserum and rhodamine-labelled a -bungarotoxin, show that
a -dystrobrevin-1 is expressed beneath the entire cell
membrane but is enriched in spontaneously occurring AChR
clusters (Fig. 5A,B). The clusters were between 2 and 20 m m
in size, indicating that they were mature, so-called
macroclusters (Phillips et al., 1993). Similarly, b -dystroglycan
staining was concentrated in AChR-rich clusters and along the
cell surface (Fig. 5E). Interestingly, dystrophin did not appear
to be in AChR-rich clusters but was relatively evenly
distributed beneath the cell surface (Fig. 5C). In contrast,
utrophin staining is concentrated in AChR-rich domains and is
only weakly detectable beneath the cell surface (Fig. 5G,H).
Thus, a -dystrobrevin-1 is expressed at the surface of C2
myotubes and is concentrated in to AChR-rich domains
alongside utrophin, suggesting that these proteins may form a
complex.
Co-immunoprecipitation of a -dystrobrevin-1 and
utrophin in C2 myotubes
To show that a -dystrobrevin-1 and utrophin form a complex in
C2 myotubes, co-immunoprecipitation experiments were
2600 R. Nawrotzki and otherscarried out using 500 m g of proteins derived from differentiated
day-8 C2 myotubes. As shown in Fig. 6 (db-1), utrophin was
specifically co-immunoprecipitated using the anti- a -
dystrobrevin-1 antiserum. Utrophin was not detected in
immunoprecipitates formed with pre-immune serum or without
a primary antibody (Fig. 6, pre, no Ab). a -dystrobrevin and
utrophin also co-immunoprecipitate in extracts from adult
mouse lung (data not shown), a tissue particularly rich in
utrophin (Blake et al., 1996). Thus, in C2 myotubes a -
dystrobrevin-1 and utrophin are physically associated and co-
localise in AChR-rich membrane domains.
Agrin-induced clustering of a -dystrobrevin-1 in C2
myotubes
To determine whether the a -dystrobrevin isoforms were
directly responsible for AChR cluster formation, C2 myoblasts
were transfected with epitope-tagged expression constructsFig. 2. Localisation of a -dystrobrevin-1 and -2
in skeletal muscle. The distribution of a -
dystrobrevin-1 in normal C57 (A,B) or
dystrophin-deficient mdx muscle (C,D) was
determined with the a 1CT-FP antiserum.
Endplate regions were identified by labelling
with a -bungarotoxin (B and D). Note the
absence of a -dystrobrevin-1 from the
sarcolemma in mdx muscle, except in some
revertant fibres. (E-H) Distribution of a -
dystrobrevin-1 in normal C57 (E,F) or mdx
muscle (G,H), determined with b CT-FP
antiserum. Bar, 30 m m.encoding a -dystrobrevin-1, -2 and -3. In each case, the
expression of recombinant dystrobrevin in C2 cells failed to
promote cluster formation (data not shown, Nawrotzki, 1997).
These data suggest that a -dystrobrevin does not play an early
role in AChR clustering but may be recruited to nascent AChR
clusters in response to nerve-derived factors.
The effect of agrin on the distribution of a -dystrobrevin-1
in C2 myotubes was analysed using two recombinant 95-kDa
agrin isoforms (Gesemann et al., 1995); the clustering-
proficient isoform containing four amino acids at site A and
eight amino acids at site B (C95A4B8), and the clustering-
deficient isoform lacking these inserts (C95A0B0). Day-6
myotubes were agrin-treated as described in Materials and
methods, and the localisation of AChRs was determined by
staining with rhodamine-labelled a -bungarotoxin. Untreated
myotubes displayed, on average, three macroclusters per
microscopic field (Fig. 7A), while treatment with the C95A4B8
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Fig. 3. Co-immunoprecipitation of a -dystrobrevin-1 and dystrophin
from mouse muscle. (A) Co-immunoprecipitation of dystrophin with
a -dystrobrevin-1. Solubilised mouse muscle proteins were
precipitated with a 1CT-FP (lane 1), P6 (lane 2), anti-Nsk2 (lane 3)
or with no primary antibody (lane 4). Co-immunoprecipitated
proteins were detected with anti-dystrophin antibody P6. Dystrophin
is precipitated with the anti-a -dystrobrevin-1 antibody as well as P6.
(B) Co-immunoprecipitation of a -dystrobrevin-1 with dystrophin.
Solubilised mouse muscle proteins were precipitated with a 1CT-FP
(lane 1), P6 (lane 2), anti-Nsk2 (lane 3) or with no primary antibody
(lane 4). Co-immunoprecipitated proteins were detected with anti- a -
dystrobrevin-1 antibody a 1CT-FP. a -dystrobrevin-1 is precipitated
with the anti-dystrophin antibody P6 (lane 2) as well as with a 1CT-
FP. The IgG heavy chain is detected by the HRP-conjugated anti-
rabbit antibody as indicated.
Fig. 4. Differentially regulated expression of a -dystrobrevin-1 in C2
myotubes. Total cell extracts were prepared from C2 muscle cells at
different time points (in days, d) during myoblast fusion in culture.
30 m g of protein were separated on 8% SDS-polyacrylamide gels,
blotted and probed with antibodies against a -dystrobrevin-1 (a -db-
1), a -dystrobrevin-2 ( a -db-2), utrophin (utro), dystrophin (dys), b -
dystroglycan ( b -dg) and vimentin/desmin (vim, des). Note the
expression of a -dystrobrevin-1, utrophin and vimentin in
proliferating myoblasts (d0) and during myotube formation. In
contrast, a -dystrobrevin-2 and dystrophin are only expressed in late
myotubes (d5-d8).isoform caused a nearly tenfold increase in the number of
AChR macroclusters (Fig. 7A). The C95A0B0 isoform slightly
increased the number of clusters (Fig. 7A). Thus, C95A4B8
agrin induced the formation of AChR macroclusters and is
therefore suitable for studying the effect of agrin on the
distribution of a -dystrobrevin-1 in C2 myotubes.
Myotubes were treated with or without agrin, and the
average number of a -dystrobrevin-1 clusters per
microscopic field was determined using the anti-
dystrobrevin-1 antiserum. Untreated myotubes expressed a -
dystrobrevin-1 evenly distributed at the cell membrane and
in macroclusters, as shown in Fig. 5C,D. Treatment with
C95A4B8 agrin had a dramatic effect on the distribution of a -
dystrobrevin-1, causing a tenfold increase in the number of
macroclusters (Fig. 7A). Concomitantly, agrin stimulation
reduced the surface expression of a -dystrobrevin-1 (data not
shown). C95A0B0 agrin did not increase the number of a -
dystrobrevin-1 clusters (Fig. 7A). Double-labelling
experiments using the anti-dystrobrevin-1 antiserum and
rhodamine-labelled a -bungarotoxin show that a -
dystrobrevin-1 and AChR clusters precisely overlap in agrin-
treated C2 myotubes (Fig. 7B). Thus, agrin causes the
clustering of AChRs and a -dystrobrevin-1 into similar sub-
membranous domains in C2 muscle cells. Thus, in C2
myotubes, a -dystrobrevin-1 is re-distributed into AChR-rich
membrane domains where it may be involved in the
stabilisation of AChR aggregates.Pervanadate, but not agrin, increases tyrosine
phosphorylation of a -dystrobrevin-1
Since agrin clusters a -dystrobrevin-1, we analysed whether
agrin also stimulated its tyrosine phosphorylation. Initially, we
treated C2 myotubes with sodium peroxivanadate, a tyrosine
phosphatase inhibitor (Meier et al., 1995). a -dystrobrevin-1
was immunoprecipitated with the anti-dystrobrevin-1
antiserum and analysed on western blots using the anti-
phosphotyrosine mAb 4G10-HRP. As shown in Fig. 8 (left
lane), both a -dystrobrevin-1 isoforms, expressed in
differentiated myotubes, were phosphorylated by
peroxivanadate. Consistent with this, the presumed non-muscle
isoform contained more phosphotyrosine than the presumed
vr3-containing isoform. Control experiments show that MuSK
is also phosphorylated in pervanadate-treated C2 myotubes
(Fig. 8, middle lane).
To determine the effect of agrin on the phosphorylation of
a -dystrobrevin-1, day-6 myotubes were incubated without
agrin (0 minutes) or with 10 nM C95A4B8 agrin for 6 minutes,
30 minutes or 4 hours. This regime is suitable for detecting
tyrosine phosphorylation of MuSK (Glass et al., 1996) and
the AChR b -subunit (Wallace et al., 1991; Ferns et al., 1996).
a -dystrobrevin-1 was immunoprecipitated and analysed as
described above. As shown in Fig. 9A, we did not detect
tyrosine phosphorylation in a -dystrobrevin-1 precipitates
during 4 hours of agrin incubation (the 55-kDa band present
in all lanes of Fig. 9A-C corresponds to phosphorylated IgG
heavy chain). Re-probing of the blot in Fig. 9A with the anti-
dystrobrevin-1 antiserum shows that a -dystrobrevin-1 was
precipitated in the experiment, but not in the pre-immune
control (Fig. 9B). A control experiment was carried out using
the anti-MuSK antiserum (Meier et al., 1997). As shown in
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Fig. 5. Localisation of a -dystrobrevin-1 and associated proteins in
C2 myotubes. C2 myotubes were fixed, permeablised and double-
labelled with rhodamine-labelled a -bungarotoxin (B,D,F,H,J) and
antibodies against a -dystrobrevin-1 (A), dystrophin (C), b -
dystroglycan (E), utrophin (G) or without a primary antibody (I). All
proteins are localised at the cell membrane and in AChR-rich
domains with the exception of dystrophin, which was not found to be
clustered (B,D,F,H,J, arrows). The membrane labelling of utrophin
(G) is fainter than that of the other proteins. Bar, 16 m m.
Fig. 6. Co-immunoprecipitation of a -dystrobrevin-1 and utrophin in
C2 myotubes. 500 m g of RIPA-buffer-solubilized protein from day-8
C2 myotubes was precipitated with the anti-dystrobrevin-1 antiserum
(db-1), pre-immune serum (pre) or without antibodies (no Ab).
Immune complexes were recovered with protein A-Sepharose,
electrophoresed, blotted and probed with the utrophin-specific mAb
MANCHO3. Utrophin is specifically co-immunoprecipitated with a -
dystrobrevin-1 (db-1). A loading control (C2 lysate) indicates the
size of endogenous utrophin in C2 myotubes. The size of myosin
heavy chain (in kDa) is indicated.Fig. 7C, 6 minutes incubation with C95A4B8 agrin is sufficient
to induce tyrosine phosphorylation of MuSK; maximum
levels are found after 30 minutes, and reduced levels after 4
hours, essentially as described (Glass et al., 1996). Thus,
although agrin recruits a -dystrobrevin-1 into AChR-richdomains in C2 myotubes, it does not induce its tyrosine
phosphorylation.
DISCUSSION
In this paper we describe the analysis of a -dystrobrevin in
muscle. Adult skeletal muscle expresses three a -dystrobrevin
isoforms, a -dystrobrevin-1, -2 and -3, of which a -
dystrobrevins-1 and -2 contain the muscle expressed vr3
sequence (Blake et al., 1996). a -dystrobrevin-3 is a muscle-
expressed, truncated dystrobrevin isoform that has a short
unique C terminus. Unlike a -dystrobrevins-1 and -2, a -
dystrobrevin-3 is encoded by a single 1.7 kb transcript. The a -
dystrobrevin-3 transcript encodes a 42 kDa protein that is
expressed in skeletal and cardiac muscle. The expression of
this isoform in muscle only contrasts with the widespread
expression of a -dystrobrevins-1 and -2 in different tissues,
suggesting a specific role for a -dystrobrevin-3 in muscle.
Interestingly, the a -dystrobrevin-3 mRNA is the most abundant
transcript from the a -dystrobrevin gene expressed in adult
tissue (Fig. 1A). Since a -dystrobrevin-3 lacks the syntrophin-
binding site, a -dystrobrevin-3 is unlikely to be a dystrophin-
associated protein.
Previous studies have localised dystrobrevin-reactive
proteins to regions in skeletal muscle, similar to those
described in this report (Carr et al., 1989; Blake et al., 1996;
Peters et al., 1997a). However, the antibodies used in these
experiments were not isoform-specific but also detected other






























Fig. 7. Agrin-induced clustering of a -dystrobrevin-1 in C2
myotubes. Day-6 C2 myotubes were treated for 16 hours with 1 nM
C95A4B8 agrin, 1 nM C95A0B0 agrin, or without agrin. (A) Parallel
cultures were fixed and permeabilised, and stained with the a 1CT-FP
antiserum (dystrobrevin) or rhodamine-labelled a -bungarotoxin. In
each experiment, a -dystrobrevin-1 and AChRs were localised in
macroclusters, ranging in length from 2 to 20 m m (see B). The
number of macroclusters were counted in 20 independent
microscopic fields that contained three or more multi-nucleated
myotubes. The mean number of macroclusters (± s.e.m.) are shown.
Only treatment with the clustering-proficient C95A4B8 agrin induces
a tenfold increase of a -dystrobrevin-1 and AChR macroclusters. (B)
C2 myotubes were treated with clustering-proficient agrin as above
and double-stained with rhodamine-labelled a -bungarotoxin (upper
panel) and a 1CT-FP (lower panel). Agrin-induced clusters
containing a -dystrobrevin-1 and AChRs overlap precisely (arrows).
Bar, 30 m m.
Fig. 8. Peroxivanadate induces tyrosine phosphorylation of a -
dystrobrevin-1 and MuSK in C2 myotubes. C2 myotubes were
treated for 15 minutes with peroxivanadate. Cell lysates were
immunoprecipitated with the anti-dystrobrevin-1 antiserum (db-1),
the anti-MuSK antiserum (MuSK), or pre-immune serum (pre).
Western blots were developed with the anti-phosphotyrosine mAb
4G10. Both a -dystrobrevin-1 and MuSK are tyrosine-phosphorylated
by peroxivanadate. Note that the lower molecular mass a -
dystrobrevin-1 isoform contains more phosphotyrosine than the
higher molecular mass form. Molecular mass markers (in kDa) are
indicated on the left.antibody 13H1 was raised against the Torpedo 87K protein
(Carr et al., 1989) and detects multiple 87K/dystrobrevin-
reactive bands in different rat tissues (Kramarcy et al., 1994).
Likewise, the polyclonal antibodies 308 and 433 detect a -
dystrobrevin-1, -2 and b -dystrobrevin in various mouse tissues
(Blake et al., 1996, 1998; Peters et al., 1997a,b). Because a -
dystrobrevin-1 is the orthologue of the Torpedo 87K protein
and was initially co-purified with the AChRs from electric
organ (Carr et al., 1989; Wagner et al., 1993), we have used
specific antibodies and a cell culture system to unravel the
complex interactions between a -dystrobrevin-1 and its binding
partners in muscle.
Using C2 cells that differentiate from myoblasts to myotubes
we have shown that a -dystrobrevin-1 is located beneath the
myotube surface and is enriched in spontaneously formed
AChR-containing clusters that label with a -bungarotoxin.
Following agrin treatment, a -dystrobrevin-1 is dramatically
redistributed into AChR clusters accompanied by an
approximately tenfold increase in the number of receptor
clusters. These data show the intimate relationship between a -
dystrobrevin-1 and the AChR-containing clusters.
Relatively few proteins have been reported to be
redistributed following agrin treatment in cultured muscle cells
or in ectopically formed synapses (see Bowe and Fallon, 1995;
Meier et al., 1997). All of the proteins clustered into AChR-
rich domains by agrin treatment are key components of the
synapse. These include the erbB family of heregulin receptors
(Meier et al., 1997), the voltage-gated sodium channels (Sharp
and Caldwell, 1996) and the dystrophin-related protein
utrophin (Phillips et al., 1993). Our findings support the
hypothesis that a -dystrobrevin-1 is a structural protein at the
synapse. However, we have also shown that a -dystrobrevin-1
is a utrophin-associated protein in the C2 cells. Thus, it is
possible that a -dystrobrevin-1 becomes localised into AChR-
rich domains via a direct interaction with utrophin.
Alternatively, a -dystrobrevin-1 could recruit utrophin into
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Fig. 9. Agrin does not induce tyrosine phosphorylation of a -
dystrobrevin-1. C2 myotubes were treated with 10 nM C95A4B8 agrin
for the times indicated on the top of the figure. At each time point,
cell lysates were precipitated with the anti-dystrobrevin-1 antiserum
(A,B) or the anti-MuSK antiserum (C). In every second lane of A-C,
pre-immune serum was used. Precipitates were electrophoresed,
blotted and probed with the anti-phosphotyrosine antibody (A,C) or
the anti-dystrobrevin-1 antiserum (B). The control experiment (C)
shows that agrin phosphorylates MuSK after 6 minutes, maximum
levels are detected after 30 minutes, and phosphorylation declines
after 4 hours. In contrast, agrin does not phosphorylate a -
dystrobrevin-1 during these incubation times (A). Reprobing of the
blot in A shows that a -dystrobrevin-1 was precipitated in the
experiment (B). Note that immunoglobulin heavy chain contains high
levels of phosphotyrosine. Molecular mass markers (in kDa) are
indicated on the left.AChR-containing clusters possibly through an interaction with
an as yet unidentified kinase or adapter protein.
We have shown that agrin induces the clustering of a -
dystrobrevin-1 into AChR-rich domains in C2 myotubes, and
that this clustering is accompanied with a reduction in the
surface staining of a -dystrobrevin-1. Since agrin acts via
MuSK and the promotion of tyrosine phosphorylation (Glass
et al., 1996), we tested the hypothesis that a -dystrobrevin-1
was a substrate in the same signalling pathway. a -dystrobrevin-
1 is not phosphorylated in response to agrin stimulation,
although it can be phosphorylated by treating cells with
pervanadate. Control experiments showed that agrin induces
the phosphorylation of MuSK, ruling out the possibility that
the clustering-proficient agrin isoform used in our experimentshad lost their activity. It is possible that agrin-induced
phosphorylation of a -dystrobrevin-1 occurs later than 4 hours
of treatment. However, agrin-induced tyrosine phosphorylation
of postsynaptic proteins is a rapid process in culture, occurring
within minutes and preceding AChR clustering by several
hours (Wallace et al., 1991; Meier et al., 1995; Glass et al.,
1996). Thus, although agrin re-distributes a -dystrobrevin-1
into AChR-rich membrane domains, it does not induce its
tyrosine phosphorylation. It is now apparent that agrin only
causes the autophosphorylation of MuSK. The b subunit of the
AChR is thought to be phosphorylated by a src-related kinase
that may be activated by MuSK (Fuhrer and Hall, 1996; Altiok
et al., 1997).
Although agrin treatment failed to phosphorylate a -
dystrobrevin-1, it is known that multiple signalling pathways
are required to orchestrate synaptogenesis. These pathways
include c-src-mediated tyrosine phosphorylation and the
MAP/ras kinase cascade (Fuhrer and Hall, 1996; Altiok et al.,
1997). It remains unclear as to which signalling events are
blocked by inhibitors of tyrosine phosphorylation in muscle. It
is possible that a -dystrobrevin-1 is phosphorylated by one of
the src-family of tyrosine kinases. The Torpedo of a -
dystrobrevin-1 crossreacts with an antibody raised against the
autophosphorylation site of c-src (Wagner et al., 1993). This
antibody also crossreacts with other src-related kinases such as
yes and fyn (Fuhrer and Hall, 1996).
In addition to utrophin, a -dystrobrevin-1 is also associated
with dystrophin in muscle and C2 cells. We have shown that
a -dystrobrevin-1 behaves like a typical dystrophin-
associated protein. For example, the levels of a -
dystrobrevin-1 are severely reduced at the sarcolemma of the
mdx mouse but are retained at the NMJ, presumably through
an interaction between a -dystrobrevin-1 and utrophin (Fig.
2). In addition to dystrophin and utrophin, a -dystrobrevin-1
and -2 also bind directly to the syntrophin family of proteins
(Blake et al., 1996; Peters et al., 1997a). Whilst b 2-
syntrophin appears to be preferentially associated with
utrophin, no such selectivity can be assigned to a -
dystrobrevin-1 (Peters et al., 1997a).
The data presented in this paper demonstrate a complex
expression pattern of a -dystrobrevin in muscle and suggest that
the different a -dystrobrevin isoforms may be involved in the
organisation of specific protein complexes at the sarcolemma
and postsynaptic membrane of the NMJ. Our evidence shows
that a -dystrobrevin-1 is not involved in the early stages of
AChR cluster formation, but rather acts, together with
utrophin, in the agrin-induced maturation of the postsynaptic
cytoskeleton. A preliminary description of a -dystrobrevin-
deficient mice that have postsynaptic abnormalities similar to
those described for the utrophin-deficient mouse, supports the
data presented here (Sanes, 1997).
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